Net sales for the Q4FY21 was reported at Rs 63.16 crore
Leading animal healthcare company, Hester Biosciences reported a standalone net profit of Rs 8.86 crore for the quarter ended March 2021 as against a net profit of Rs 5 crore in the corresponding period last year – a growth of 77 per cent. Net sales for the Q4FY21 was reported at Rs 63.16 crore, a growth of 52 per cent as compared to net sales of Rs 41.43 crore in the corresponding period last year. EPS for Q4FY21 was reported at Rs. 10.41 per share.
The company can maintain healthy margins; EBITDA Margin was reported at 32.62 per cent and net profit margin at 14.03 per cent in Q4FY21. The Board of directors has recommended a dividend of Rs 10 per equity share (100 per cent) for FY21, subject to the approval of the shareholders. This dividend recommendation is in line with the company’s dividend policy to distribute a minimum of 18 per cent of the PAT.
